Full video transcriptClick to expand
Auto-generated transcript of @candacerenee__'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00When I first started trading futures, this was one thing that people used to stay gatekeeping.
- 0:05And it's just like, why would you gatekeep this?
- 0:07Because this was messing up my coins.
- 0:09But I'm going to tell you guys, so you don't make the same mistake that I did.
- 0:13Hey, everybody.
- 0:14Welcome to part two of my series.
- 0:15Oh, you want to learn how to trade futures.
- 0:18First thing that you are going to need is a broker.
- 0:20A broker is how you go to enter your trades, exit your trades, put your money in, take
- 0:24your money out.
- 0:25What I like to use is trade of a and ninja trader.
- 0:27Trade of a and ninja trader kind of work hand in hand.
- 0:30That is the only broker that I have ever used.
- 0:32There are a bunch of ones out there.
- 0:33But the most popular one that a lot of people use is trade of a and ninja trader also are
- 0:38going to need trading view.
- 0:41Trading view is how you are going to look at your charts.
- 0:44Okay.
- 0:45You can connect your trade of a or your ninja trader to your trading view and you can actually
- 0:51put in trades directly into trading view, kind of like how I did here.
- 0:56I never put in my trades in the actual trade of a app because it's just, it's a little
- 1:02bit too complicated.
- 1:03And plus this is kind of like very girly of me, but the aesthetics looks so much better
- 1:07in trading view.
- 1:08Like I saw, but one thing that a lot of people forget to get when they are trading futures
- 1:12is the CME market data subscription.
- 1:15The CME market data subscription tells you the real time futures prices.
- 1:19If you don't have the CME market data, then your trades are going to be delayed and you
- 1:25are not going to be able to see the trades in real time.
- 1:27And that is going to mess up your money.
- 1:29Comment part three if you guys want to know exactly how much money that you need to actually
- 1:34start trading futures.
GLP-1 drugs and trading content: what's actually being claimed?
Quick answer
This video contains no health, medical, or GLP-1 related content and was miscategorized under the GLP-1 label. The creator discusses retail futures trading software and market data infrastructure. No clinical review is applicable, and no health claims are present in the transcript.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 3 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and trading content: what's actually being claimed?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 drugs and trading content: what's actually being claimed? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 drugs and trading content: what's actually being claimed?" from Candace | Business & Lifestyle. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video contains no health, medical, or GLP-1 related content and was miscategorized under the GLP-1 label.
The reason this review is not generic is the source wording and the canonical claim label "glp1 futurestrading futuresforbeginners tradingforbeginners daytr." In this clip, the useful excerpt is: "When I first started trading futures, this was one thing that people used to stay gatekeeping." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video contains no health, medical, or GLP-1 related content and was miscategorized under the GLP-1 label.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video contains no health, medical, or GLP-1 related content and was miscategorized under the GLP-1 label. The creator discusses retail futures trading software and market data infrastructure. No clinical review is applicable, and no health claims are present in the transcript.
- This video contains zero health or GLP-1 related content and was miscategorized. No medical fact-check applies.
- CME Group charges retail traders for real-time futures data. Without a paid subscription, most platforms show prices on a 10-minute delay by default.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- This video contains zero health or GLP-1 related content and was miscategorized. No medical fact-check applies.
- CME Group charges retail traders for real-time futures data. Without a paid subscription, most platforms show prices on a 10-minute delay by default.
- Tradovate non-professional CME data subscriptions cost approximately $7 to $14 per month depending on the product bundle, a cost beginners often overlook.
- A single E-mini S&P 500 futures contract controls roughly $100,000 in notional value due to leverage. Losses can exceed initial deposits.
- A 2023 CFTC report found retail traders disproportionately appear on the losing side of short-term futures positions as retail participation has grown since 2020.
- The three-part setup she describes (broker, charting platform, real-time data) reflects how retail futures infrastructure actually works. The technical claims in this video are accurate.
- The most financially consequential information, minimum capital requirements and risk exposure, is deferred to a future video rather than addressed here.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @candacerenee__ actually say?
This video has nothing to do with GLP-1 medications. @candacerenee__ is talking about futures trading setup, not weight loss drugs or metabolic health. She walks through three tools she says beginners need: a broker (she uses Tradovate and NinjaTrader), a charting platform (TradingView), and a CME market data subscription. Her core claim is that without the CME subscription, "your trades are going to be delayed and you are not going to be able to see the trades in real time." She frames the CME data as a commonly gatekept secret that cost her money before she figured it out.
This is a trading education video mislabeled under the GLP-1 category. There are no health claims here, no references to medications, and nothing that falls under the scope of a regulated telehealth platform's clinical fact-checking mandate.
Does the science back this up?
There is no clinical science to evaluate here. This is financial content, not health content. That said, her factual claims about trading infrastructure are worth checking on their own merits, because bad trading advice causes real financial harm.
On the technical side, she is correct that CME Group charges for real-time futures data. Without a paid data subscription through a broker or data provider, most retail platforms display futures prices on a 10-minute delay by default. This is standard industry practice, confirmed by CME Group's own data licensing documentation. Tradovate and NinjaTrader both require users to activate a CME data subscription to receive live tick-by-tick pricing. TradingView also supports direct order routing to Tradovate, which is consistent with her claim that you can "put in trades directly into trading view." None of these are controversial assertions. They reflect how these platforms actually work.
What did they get wrong (or right)?
Honestly, she got the technical basics right. The broker, charting platform, and real-time data subscription are the three foundational layers of a retail futures trading setup. She is not overstating what CME data does, and she is not making any performance claims about returns.
What she glosses over is worth flagging. She says you need a broker and a CME subscription, but she does not mention that CME data subscription fees vary by product. Real-time data for equity index futures (like the E-mini S&P 500) costs differently than agricultural or energy futures. Retail non-professional subscriptions through Tradovate run roughly $7 to $14 per month depending on the bundle, but this adds up, and beginners often do not factor it into their cost of trading. She also does not mention that Tradovate charges per-contract fees on active accounts, which matters for anyone calculating whether they can actually afford to trade futures at all.
She teases "exactly how much money you need" for part three, which is the more consequential question she has not answered yet.
What should you actually know?
If you are a beginner drawn to this video, the setup she describes is legitimate and commonly used. But futures trading carries risks that a 60-second TikTok cannot responsibly cover. Retail futures traders can lose more than their initial deposit, because futures are leveraged instruments. A single E-mini S&P 500 contract controls roughly $100,000 in notional value. The CME data subscription is the least of your costs.
A 2023 report from the Commodity Futures Trading Commission noted that retail participation in futures markets has increased significantly since 2020, and that retail traders disproportionately appear on the losing side of short-term futures positions. That is not a reason to never trade, but it is a reason to treat "part three" as the most important video in this series, not the setup tutorial.
The tools she recommends are real and used by actual traders. The missing context is about risk, not about which broker to use.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Candace | Business & Lifestyle · TikTok creator
30.1K views on this video
#futurestrading #futuresforbeginners #tradingforbeginners #daytradersoftiktok #learntotrade
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about this video contains zero health?
This video contains zero health or GLP-1 related content and was miscategorized. No medical fact-check applies.
What does the video say about cme group charges retail traders for real-time futures data. without?
CME Group charges retail traders for real-time futures data. Without a paid subscription, most platforms show prices on a 10-minute delay by default.
What does the video say about tradovate non-professional cme data subscriptions cost approximately $7 to $14?
Tradovate non-professional CME data subscriptions cost approximately $7 to $14 per month depending on the product bundle, a cost beginners often overlook.
What does the video say about a single e-mini s&p 500 futures contract controls roughly $100,000?
A single E-mini S&P 500 futures contract controls roughly $100,000 in notional value due to leverage. Losses can exceed initial deposits.
What does the video say about a 2023 cftc report found retail traders disproportionately appear on?
A 2023 CFTC report found retail traders disproportionately appear on the losing side of short-term futures positions as retail participation has grown since 2020.
What does the video say about the three-part setup she describes (broker, charting platform, real-time data)?
The three-part setup she describes (broker, charting platform, real-time data) reflects how retail futures infrastructure actually works. The technical claims in this video are accurate.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Candace | Business & Lifestyle, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.